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Plasticity: Implications for opioid and
other pharmacological interventions
in specific pain states
Anthony H. Dickenson
Department of Pharmacology, University College London,
London WC1E 6BT, United Kingdom
Electronic mail: anthony.dickenson6ucl.ac.uk
Abstract: The spinal mechanisms of action of opioids under normal conditions are reasonably well understood. The spinal effects of
opioids can be enhanced or reduced depending on pathology and activity in other segmental and nonsegmental pathways. This plasticity
will be considered in relation to the control of different pain states using opioids. The complex and contradictory findings on the
supraspinal actions of opioids are explicable in terms of heterogeneous descending pathways to different spinal targets using multiple
transmitters and receptors – therefore opioids can both increase and decrease activity in descending pathways. These pathways could
exhibit considerable plasticity. There is increasing evidence that delta opioid receptor agonists have the potential to replace morphine as
major analgesics with reduced side-effect profiles. The concept of preemptive analgesia, based on preventing the induction of some of the
negative plastic influences on opioid controls and the detrimental effects of pain, is sound, but experimental verification in the clinical
setting is difficult. For example, a delayed compensatory upregulation of inhibitory systems, particularly in inflammation, may counter
persistent painful inputs. Combination therapy with opioids may be beneficial in many pain states where either negative influences are
blocked or inhibitory controls are enhanced. Finally, developmental aspects of these systems are discussed in connection with the
treatment of pain in young children, where inhibitory systems in the spinal cord are immature.
Keywords: analgesia; cholecystokinin; development of pain; excitatory amino acids; hypersensitivity; nociception; opioids; peptides;
spinal cord
1. Introduction: Plasticity in pain
The two major types of clinical pain arise from distinct
events in the periphery. Inflammatory pain arises from
tissue damage such as that produced by trauma, surgery,
childbirth, or invasion of tissue by a tumour. The second
type of pain is termed “neuropathic” pain and results from
damage to a nerve; trauma, surgery, and cancer can also
cause this type of pain. In the case of inflammatory pain, the
damage to tissue causes the local production of a number of
chemical mediators that sensitize and/or activate the pe-
ripheral endings of nociceptive C-fibres (Dray et al. 1994).
With neuropathic pain, however, activity is set up in the
nerve itself. Regardless of the origin of the pain, impulses
are conveyed to the first synapse in the dorsal horn of the
spinal cord, where the interplay between excitatory and
inhibitory events determines the ascending messages that
are transmitted to higher centres. However, descending
controls from the brain stem can be triggered and further
alter processing in the spinal cord (Besson & Chaouch
1987; Fields et al. 1988). Opioid analgesics can exert
controls on these events by direct actions on the spinal cord
but can also interact with systems at the origins of the
descending controls (Duggan & North 1984; Dickenson
1994a). Thus, at a number of levels there is the potential for
alteration in the messages that ultimately give rise to the
final sensation of pain. This article is an attempt to bring
together some of the interactions between excitatory and
inhibitory events to explain some of the different charac-
teristics of inflammatory and neuropathic pain and to
investigate how alterations in these systems can give rise to
difficulties in treating certain pains, especially neuropathic
pains.
It is well established that the repertoire of the adult
central nervous system (CNS) is not fixed and immutable.
Plasticity, the ability of central nervous function to change
in response to internal and external events, can be due to
alterations in connectivity (Woolf & Doubell 1994; Dray et
al. 1994). Plasticity is of great relevance to the control of
these different pain states (McQuay & Dickenson 1990),
yet plasticity can also result from a relatively rapid induc-
tion and activation of different pharmacological systems
under different circumstances (Dickenson 1994a; 1994b;
McMahon et al. 1993; Price et al. 1994b; Woolf 1994). This
target article will concentrate on interactions between
spinal pharmacological systems and opioid analgesia. States
of increased pain transmission, central hypersensitive states
(Woolf 1983), can result from activation of spinal systems
that do not participate in the responses to brief stimuli. In
these cases where the level of excitatory transmission is
augmented, opioid inhibitions will need to be increased to
compensate. Consequently, the actions of opioids are not
fixed but highly dependent on activity in other transmitter
systems that in turn appear to be influenced by different
types of pain. This target article will consider this plasticity
in relation to the control of different pain states using
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opioids as a theme. The main emphasis will be on results
from models of acute and more prolonged pains such as
that arising from inflammation and neuropathy and I will
attempt to discuss why the actions of opioids may differ in
different pain states. Thus, pain arising from tissue damage
(inflammatory nociceptive pain) can respond well to
opioids whereas neuropathic pain (arising from peripheral
or central nerve damage) and allodynia (where touch is
perceived as pain) can show poor opioid sensitivity.
2. Opioid receptors
Opioids act by activating three opioid receptors: the mu,
the delta, and the kappa (Kosterlitz 1985). Whereas the
endogenous opioid peptides, the natural ligands for the
receptors – namely the enkephalins, dynorphins, and
endorphin family – are not entirely specific for any one of
these receptors, a number of synthetic agents with high
selectivity are available to study the individual receptors
(Dickenson 1994a; Kosterlitz 1985). Neurones producing
the different opioids can be unequivocally identified now
using messenger RNA probes for the precursor propep-
tides. Opioid peptide synthesis can be altered in animal
models of different pain states, for example, dynorphin
levels in the spinal cord during inflammation are increased
enormously due to the switching on of the gene for the
synthesis of the parent propeptide (Dubner & Ruda 1992).
The biological lifetimes of the endogenous opioids, partic-
ularly the enkephalins, are brief due to rapid peptidase
degradation. It is now possible to protect the enkephalins
from breakdown by the use of peptidase inhibitors, some of
which are now active by systemic routes (Roques et al.
1993). The use of these agents together with the synthesis
of stable analogues of the endogenous opioids themselves
has provided the means for the study of the roles and
function of opioids and their receptors with far greater
selectivity than with only the endogenous opioids.
2.1. Mechanisms of opioid analgesia. There are three key
mechanisms of action for opioids. The underlying events by
which opioids interfere with the transmission of pain are
the same as the mechanisms by which opioids cause their
other actions, including side effects (Dickenson 1994a;
Duggan & North 1984). These are:
1. A presynaptic action on the terminals of neurones
whereby transmitter release is reduced by activation of
opioid receptors. In tissues where relative receptor location
has been gauged, the number of presynaptic opioid sites
predominates over postsynaptic locations.
2. There are significant numbers of postsynaptic opioid
receptors and after activation the resultant hyperpolarisa-
tion reduces evoked activity in the neuronal pathways. The
postsynaptic effects can be on cell bodies of output neu-
rones, interneurones, or dendrites.
3. An alternative postsynaptic action involves disinhibi-
tion: in a circuit of two neurones, where the second cell is
held in check by an inhibitory neurone, opioid inhibition of
the first neurone allows the second cell to become active.
These actions produce analgesia at a number of sites in
the nervous system. The two key sites would appear to be a
spinal and a midbrain/brain stem action in normal circum-
stances, but an additional peripheral site in inflamed tissue
can also be induced.
3. Spinal analgesia
Opioid receptors in the spinal cord are a critical site in the
production of analgesia. Spinal opioid analgesia demon-
strates how basic research in animals can have a rapid and
important application to the clinical relief of pain. Opioid
inhibition of nociceptive neurones in spinal animals and
then evidence for analgesia following epidural and intrathe-
cal opioids in animals was soon followed by clinical usage
(Besson & Chaouch 1987; Yaksh & Nouiehed 1985).
3.1. Presynaptic actions. The highest levels of opioid
receptors in the spinal cord are around the C-fibre terminal
zones in lamina 1 and the substantia gelatinosa with lower
levels found in deeper layers. The best current estimates
suggest that the mu receptor forms 70%, the delta 24%, and
the kappa 6% of the total opioid sites in the rat spinal cord
(Besse et al. 1990). The idea that kappa levels are higher in
the mouse and guinea pig spinal cord has been put forward.
However, studies in species other than the rat have not
been carried out with the most selective ligands for the
receptors and so may not represent the true relative distri-
bution of the receptors. We lack systematic quantitative
studies in a number of species on the relative distribution of
the receptors at a variety of CNS sites. Recent studies using
probes for the selected sequences of the delta receptor
have shown unequivocally that many of these receptors are
located presynaptically on afferents and in close apposition
to enkephalin-containing cells (Dado et al. 1993). In addi-
tion, spinal application of antisense to the delta receptor has
shown that this leads to a marked reduction in delta-
mediated analgesia without alteration of the effects of
morphine (Uhl et al. 1994).
The relative numbers of presynaptic and postsynaptic
receptors can be calculated after nerve section and the
former predominate. The proportions of presynaptic opioid
receptors in the spinal cord varies from 70% to 50%, with
over 70% of the total mu receptor sites (Besse et al. 1990),
along with large numbers of delta receptors (Dado et al.
1993), on the afferent terminals. Given the large number of
receptors, it is not surprising that evidence for a presynaptic
action of opioids emerges from studies of opioid inhibition
of C-fibre evoked release of transmitters (substance P and
glutamate) as well as in vitro and in vivo electrophysiologi-
cal studies (Dickenson 1994a; Yaksh & Malmberg 1994;
Yaksh & Nouiehed 1985). However, other approaches have
failed to demonstrate this presynaptic action (e.g., Lang et
al. 1991).
Presynaptic actions on transmitter release result from an
opening of potassium channels (mu and delta receptors) or
a closing of calcium channels (kappa), both of which lead to
a reduction in calcium influx into C-fibre terminals – thus
diminishing transmitter release (North 1989). C-fibres are
believed to release a number of coexisting transmitters
including the tachykinins, excitatory amino acids, and a
number of excitatory peptides that act on multiple recep-
tors (Besson & Chaouch 1987; Dickenson 1994a; Dray et al.
1994). Consequently, the presynaptic action of opioid’s
ability to reduce the release of many transmitters will be a
highly effective route to analgesia, since it will be equivalent
to the block of multiple postsynaptic receptors. It is not
probable, therefore, that any single antagonist of one of
these postsynaptic receptors will have sufficient efficacy to
compete with the opioids as do powerful analgesics in acute
and chronic pains. An exception to this is likely to be agents
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acting directly, or indirectly, to modulate the N-methyl-
D-aspartate (NMDA) receptor in pains where central hy-
persensitivity, an augmented spinal response to a low or
moderate afferent input, is generated.
Section of a peripheral nerve will lead to degeneration of
the nerve and the presynaptic receptors synthesized in the
dorsal root ganglion will be lost (reducing mu opioid recep-
tor sites in the dorsal horn by 70%; see Besse et al. 1990). It
would be beneficial to know if less severe nerve damage
impairs the production of functional opioid receptors.
However, in animal models where the presynaptic opioid
receptors have been removed by prior rhizotomy, whether
electrophysiological with systemic dosing in spinal prepara-
tions (Lombard & Besson 1989) or behavioural with spinal
application (Xu & Wiesenfeld-Hallin 1991), morphine is
still effective, although higher doses are required in the
former case. Thus when there is a loss of opioid receptors,
there will be a reduction in opioid actions that should
predictably be overcome by dose escalation (Lombard &
Besson 1989). If nerve damage does lead to a loss of some of
the spinal opioid receptors, one could predict that opioid
delivery to supraspinal sites would target the normal popu-
lation of supraspinal receptors. In clinical practice there is a
reduced systemic opioid effectiveness in neuropathic pains
(Arner & Meyerson 1988) that can be overcome by increas-
ing the dose in some circumstances ( Jadad et al. 1992;
Portenoy et al. 1990). Dose increases may not always be
possible, since side effects may become intolerable. When
the side effects can be controlled and increase in dose does
not overcome the pain, we have to suspect that opioid
receptor loss or dysfunction is not the only factor.
3.2. Postsynaptic actions. Evidence for functional opioid
actions at postsynaptic receptors is based on electro-
physiological and behavioural approaches (Duggan &
North 1984; Lombard & Besson 1989). Postsynaptic hyper-
polarisations again result via the opening of K1 channels or
the closing of calcium channels (North 1989). These recep-
tors could hyperpolarise the dendrites of projection neu-
rones and interneurones (both would be selective for nox-
ious transmission) as well as the cell body of projection cells
that may not be selective for nociceptive inputs, since many
but not all neurones in the dorsal horn receive both
nociceptive and tactile inputs.
An important indirect postsynaptic action is the opioid
disinhibitory effect mediated via GABA and enkephalin
neurones in the substantia gelatinosa, which in turn leads to
an inhibition of output neurones. Thus in this instance,
neurones can be recorded in the substantia gelatinosa that
are facilitated by opioids, an action that requires GABAA
receptor function. There is both morphological and electro-
physiological evidence to support this action (see Magnu-
son & Dickenson 1991).
These postsynaptic actions of opioids present some prob-
lems of interpretation, since any direct hyperpolarisation of
a cell soma would inhibit all responses of the cell including
the innocuous inputs onto convergent or multireceptive
cells. However, many of the opioid receptors in the substan-
tia gelatinosa could be on the dendrites of the deep cells
penetrating into the C-fibre terminal zone; inhibitory ef-
fects here would also be selective, as they are likely to be
spatially distinct from the large fibre inputs. Another possi-
bility is that the postsynaptic disinhibitory effects of opioids
selectively feed onto nociceptive circuitry. When allodynia
and some of the hyperalgesias are transmitted through
A-fibre afferents, a poor sensitivity to opioids might be
found (Yaksh 1989), since the only opioid control of A-fibre
inputs is via the relatively small number of postsynaptic
receptors on the output neurones (Besson & Chaouch
1987; Duggan & North 1984). Doses of morphine that
abolish C-fibre-evoked responses in normal animals have
only minor effects on A-fibre activity (Dickenson & Sullivan
1986). In these pain states, novel nonopioid therapy di-
rected at the spinal systems generating the tactile-evoked
pain may have to be considered (Yaksh 1989).
4. Alternatives to morphine?
Surprisingly, it is unclear whether different opioids may
have slightly different ranges of pharmacological actions
that could allow a choice of opioid for different pains.
Clinical studies comparing different opioids in different
pain states are needed. Morphine at physiological doses
probably acts only at the mu receptor. This drug has a high
affinity for the mu receptor, a relative affinity of 50 times
less for the delta receptor, and a minimal affinity for the
kappa receptor (Kosterlitz 1985). Thus relatively nonselec-
tive effects could occur with very high doses such as those
achieved both in neurochemical and in binding studies
where non-mu effects of morphine have been reported.
However, in vivo, doses of spinal morphine, which are
sufficient to abolish the C-fibre-evoked responses of dorsal
horn nociceptive neurones, are probably entirely mu recep-
tor mediated. In support of this, there is no evidence for
mu–delta cross tolerance from physiological studies (Kalso
et al. 1993). Since morphine is the standard opioid for
clinical practice, plasticity that is related to mu receptor
mechanisms is of great importance (Dickenson 1994a).
Possible opioid drugs that act on receptors other than the
mu receptor for morphine are analgesics with reduced
morphine-like side-effect profiles. As is the case with any
transmitter system, the greater the number of receptors the
greater the chance that the desirable effects can be sepa-
rated from the unwanted effects. With opioid receptors, a
further division of the receptors from the main three – the
mu, delta, and kappa – has been proposed. The mu recep-
tor has been suggested to consist of a mu 1 and a mu 2
subtype (Pasternak & Wood 1986); the delta has been also
subdivided and the kappa receptor has been divided into
three subtypes ( Jiang et al. 1991; Traynor 1989). Whether
these subtypes have functional consequences remains to be
seen: physiological consequences are not yet discerned
except for the delta subtypes where there is evidence for
differential effects of the two receptors ( Jiang et al. 1991).
The recent cloning of the opioid receptors (Uhl et al. 1994)
will further facilitate this task, because probes based on the
receptor sequence will provide unequivocal proof of loca-
tion of the particular receptor and important insights into
the mechanisms of opioid actions and the existence of
subtypes. At the present time there is no evidence from the
cloning studies for receptor subtypes: the receptors that
have been isolated, whether mu, delta or kappa, were single
identical species. There may be alternative splicing that
produces the subtypes or local neuronal tissue environ-
ments that allow the subtypes to be expressed and, in
addition, the cell lines used so far may underestimate the
variability within the opioid receptor family (Uhl et al.
1994). However, it is known that the rat and mouse opioid
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receptors are, as far as can be determined, identical in
structure and pharmacology to the human receptors, fur-
ther verifying the important links between animal studies
and clinical practice (Uhl et al. 1994).
4.1. Delta opioids. Antagonists for the opioid receptors
have demonstrated the independence of mu, delta, and
kappa receptors in terms of antinociception, although there
have been problems demonstrating kappa receptor agonist
effects in some studies (Millan 1990). The independent
analgesic effects following activation of non-mu receptors
indicate potential for opioid analgesics that are delta or
kappa agonists. Kappa opioids are not always particularly
effective analgesics in animals and this appears to be
reflected in the initial early clinical studies with these drugs
in humans. The delta receptor may well be an important
target for novel opioid therapy. Animal studies have shown
that opioids selective for the delta receptor can equal the
analgesic effects of morphine by actions at both spinal and
supraspinal sites in a number of nociceptive tests (Dicken-
son et al. 1987; Jiang et al. 1991; Sullivan et al. 1989a). One
could also predict reduced respiratory depression and gas-
trointestinal effects of delta as compared to mu opioids.
There are now reports of potent and selective nonpeptide
delta opioids, which have been tested in a number of
paradigms in animals. A highly selective delta opioid, SNC
80, has been produced. It was found to be effective by
central and systemic (including oral administration) routes,
and analgesic effects were reversed by a number of delta
but not mu opioid receptor antagonists. Importantly, in
tests of respiratory function, SNC 80 stimulated rather than
reduced respiratory rate in sheep (Bilsky et al. 1995). The
potential of delta opioids is therefore high and eventually
delta opioids may be clinical alternatives to morphine. As
will be discussed in sections 5 and 7.1, there are suggestions
that some of the reduced effects of morphine in neuropathy
may be due to negative effects of cholecystokinin on mu
receptors – these effects do not extend to delta-mediated
actions. Consequently, it is possible that delta opioids may
be better analgesics than mu opioids in the treatment of
neuropathic pains.
4.2. Endogenous opioids. What about endogenous opioids?
The enkephalins are rapidly degraded by membrane-bound
peptidases. The synthesis of peptidase inhibitors has been a
successful strategy, so that kelatorphan, a mixed peptidase
inhibitor inhibiting at least two of the important breakdown
enzymes, affords almost complete protection to the en-
kephalins (Roques et al. 1993). The spinal application of the
inhibitor produces a reduction of nociceptive responses of
cells, with the pool of enkephalins protected by the inhibitor
likely to be derived from both a segmental release and from
descending pathways activated by the stimulus. The inhibi-
tions are reversed by a selective delta antagonist (Dickenson
et al. 1987a). The very recent reports of RB 101, a system-
ically active mixed peptidase inhibitor, constitutes the next
stage toward the clinical application of this novel approach to
pain relief. In addition, the side-effect profile of RB 101
appears to be unlike that of morphine in terms of physical
and psychological dependence (Roques et al. 1993).
4.3. Novel peripheral analgesia. Whereas opioids lack pe-
ripheral actions in undamaged tissue, there is now good
evidence that the consequences of inflammation can reveal
a novel site of opioid action that appears rapidly (Stein
1994). The synthesis of opioid receptors occurs in dorsal
root ganglion cells as well as other locations in the body.
These receptors are transported in the fine afferent fibres
in both directions; the centrally directed receptors become
the presynaptic receptors and the peripherally transported
receptors somehow become active only following inflam-
mation. The relative effectiveness of mu, delta, and kappa
receptor activation to elicit peripheral analgesia varies
between models, but in arthritic states all three are active
(Stein et al. 1989). Alongside the appearance of the func-
tional opioid receptors on afferent nerves, the arrival of
endogenous opioid peptides at the injury site seems to be
related to immune cell proliferation. Thus opioids unable to
penetrate the CNS and, as a result, devoid of central side
effects may be good analgesics in inflammatory states via
these peripheral sites. There have now been a number of
clinical studies on this effect, the bulk of which have been
positive. Thus the local application of morphine into the
knee joint in patients has been shown to produce a local
analgesic effect. A recent study has also shown that the
degree of analgesia can be related to the amount of tissue
damage and, presumably, to the degree of inflammation
(Stein 1994). Peripherally acting opioids may then have
potential analgesic effects in inflammation (Stein 1994;
Stein et al. 1989).
4.4. Supraspinal analgesia. The first demonstration of
opioid actions within the CNS consisted of analgesia seen
following intraventricular morphine. Numerous supraspi-
nal sites of opioid analgesia have been established (Besson
& Chaouch 1987). These have now been localized to areas
in the medial brain stem around the nucleus raphe magnus
and extending rostrally to periaqueductal and periventricu-
lar grey and other areas with the monoamines appearing to
be critical transmitters in these pathways (Yaksh et al.
1988). The roles of these areas in morphine analgesia have
been based on microinjection studies and the ability of
naloxone, when applied locally into these areas, to reduce
the effects of systemic morphine.
The mechanisms of action in opioids at these supraspinal
levels still is unclear, particularly about how they interact
with descending inhibitory controls. Whereas opioid in-
duced increases and decreases in descending inhibitory
controls have been reported, the roles of these descending
pathways in different models of various pain states are
unknown. We need more information on the physiological
and pharmacological bases for supraspinal analgesia in
animal models of persistent pain in order to form a basis for
the potential use of manipulation of the monoamines in
difficult clinical pains.
Examination of the anatomy and the pharmacology of the
descending systems may provide a basis for these disparate
results with regard to opioid interactions with descending
controls. First, descending controls originate from many
different areas of the brain stem and midbrain and, in
addition, a complex pharmacology exists in these descending
pathways (Yaksh et al. 1988). Noradrenaline, 5HT, en-
kephalin, and substance P are involved, all coexisting in some
neurones projecting from the brain stem and midbrain to the
spinal cord. In addition to interactions between these
transmitters, there are a number of local transmitter systems
(cholinergic, GABAergic, and opioid) in the nuclei where
the descending controls originate. Direct opioid inhibitions
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or indirect disinhibitions could result from local opioid
actions in these supraspinal areas. These opposite effects
could themselves be on inhibitory and/or excitatory path-
ways. A further complexity is that the monoamines have a
number of receptors at the spinal terminal sites that when
activated could inhibit or excite depending on the receptor –
an additional complication is the presence of autoreceptor or
heteroreceptor control of the release of transmitter at these
terminal sites. Whether the postsynaptic receptors are on
excitatory or inhibitory elements is also important. Conse-
quently the problem is not to discern the direction of effect
of opioids on these systems but to understand the physiologi-
cal roles and consequences of the mixed opioid actions on
these multiple pathways (Dickenson 1994a).
Consideration of the direction of effect of the spinal
monoamine receptors serves to illustrate these points. In
the case of noradrenaline, there is a general consensus that,
notwithstanding a possible role of the alpha-1 receptors, the
predominant spinal targets for the transmitter are alpha-2
receptors located in the spinal cord, postsynaptically to the
noradrenergic terminals. In a similar manner to the opioid
receptors and the afferent nociceptive fibres, these recep-
tors are located both presynaptically and postsynaptically
on spinal sensory circuits; there is ample evidence for
alpha-2 agonists being effective analgesics in a number of
animal models of acute and more persistent pains. In
addition, there is little doubt that alpha-2 agonists synergize
with morphine, probably as a result of dual activation of
separate receptors with similar locations and effector
mechanisms (Dickenson & Sullivan 1993; Yaksh & Malm-
berg 1994). Relatively little is known about the driving force
behind pain-related changes in noradrenergic activity in
these models. An exception is a report of increased alpha-2
mediated activity in inflammation, but it does not contrib-
ute to enhanced spinal opioid effectiveness (Stanfa &
Dickenson 1994a). There may, however, be a supraspinal
site of action of noradrenaline in enhancing opioid actions
(Hylden et al. 1991).
The effectiveness of tricyclic antidepressants (TADS) for
pain relief in humans possibly relates to enhancement of
the availability of noradrenaline and serotonin. This is
where the problems arise. The number of receptors for
serotonin or 5-hydroxytryptamine (5HT) increases on a
regular basis. Presently, there are at least seven major
receptors with over 20 subtypes. The receptor that under-
lies descending antinociception at the spinal level is un-
known. Thus, increases in 5HT levels in the cord will
activate all the receptors irrespective of whether they are
excitatory or inhibitory. Knowledge of the particular roles of
the monoamine receptors may potentially lead to better
therapeutic efficacy by agents (or combinations thereof )
acting on particular receptors rather than the indirect
indiscriminate activation of multiple receptors produced by
the TADS (Max 1994).
Bearing in mind these complexities, how do opioids
interact with descending pathways? As many of the sites of
opioid actions at supraspinal sites overlap with areas where
descending inhibitory controls originate, the simplest situa-
tion is that supraspinal opioids increase these descending
monoamine inhibitions; in turn these block spinal pain
transmission by actions at inhibitory spinal receptors. For
opioids to increase descending inhibitions, the mechanism
will have to be via disinhibitions (Fields et al. 1988). The
clearest demonstration of supraspinal descending inhibi-
tory controls that are increased by morphine is that the
spinal induction of c-fos, used as a marker of noxious
evoked activity, was found to be very clearly reduced by
intraventricular morphine (Gogas et al. 1991).
There are other studies, however, that do not find this
direction of effect. Diffuse noxious inhibitory controls
(DNICs) are descending controls induced by heteroseg-
mental noxious stimulation and partly involve both opioid
and serotoninergic mechanisms. Morphine, either given
directly into supraspinal tissues or at low systemic doses
without direct spinal actions, reduces these descending
controls (Le Bars & Villaneuva 1988). There are consider-
able difficulties, therefore, in arriving at a simple consensus
as to the direction of effect of opioids on descending control
systems. However, as discussed above, the multiplicity of
these descending controls in terms of their anatomy, their
pharmacology, and their spinal projections form a frame-
work in which the various directions of effect of opioids can
be incorporated. There is no doubt that whatever the
mechanism, supraspinal opioids produce behavioural anal-
gesia (Besson & Chaouch 1987; Yaksh et al. 1988).
It is highly likely that both the level of pain transmission
and the effectiveness of opioids in different pain states is
determined by alterations in descending control pathways.
Other than studies on alpha-2 adrenoceptors, we are igno-
rant of the extent of plasticity in these systems.
5. Plasticity in opioid controls
Using the previously articulated framework of opioid ef-
fects and mechanisms on which to consider plasticity in
opioid systems, it is pertinent to consider in this section
particular pain states where there is evidence for changed
opioid effectiveness. Why are opioids sometimes poorly
effective in neuropathic pain states in man and animals
(Arner & Meyerson 1988; Jadad et al. 1992; Portenoy et al.
1990)? Yet there is good evidence that in a number of
inflammatory models opioids are more effective than in
normal animals (Dickenson 1994a). In addition, as there
are transmitter systems in the CNS that can reduce opioid
effectiveness, preemptive analgesia should stop the induc-
tion of these systems and so provide better pain relief: Why
has it been so difficult to provide clear and marked clinical
benefits for this approach (McQuay 1994)?
The analgesic effects of morphine can vary in different
pain states. The mechanisms behind these changes have
been elusive, but their identification and eventual manipu-
lation may be of considerable clinical benefit. First, let us
consider the pharmacological systems that can interfere
with opioid effectiveness, bearing in mind that pathology
can also play a role in nerve section and the loss in number
of presynaptically located opioid receptors. There appear to
be four major pharmacological factors:
1. Interference with mu receptor function by the metab-
olite of morphine, morphine-3-glucuronide (M3G). This
has been proposed on the basis of behavioural studies but
is not supported by electrophysiological and clinical
studies.
2. Changes in the levels of the nonopioid peptides,
FLFQPQRFamide and/or cholecystokinin (CCK), either
spinally where there is very strong evidence for CCK as a
regulator of morphine analgesia, or supraspinally as a more
global negative influence on opioid actions.
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3. Increased levels of the opioid peptide, dynorphin,
which has been shown to occur after persistent pain. In
theory this peptide can reduce mu opioid analgesia, but the
physiological role of dynorphin as an opioid modulator is
not good.
4. An excess of excitatory activity, so that a spinally
generated hypersensitive state is induced, against which
opioid controls are insufficiently efficacious. The
N-methyl-D-aspartate (NMDA) receptor is a very strong
candidate for the final common path for generation of this
state, and there is poor opioid sensitivity to a number of
electrophysiological and behavioural measures of pain
where NMDA receptor activation has been induced.
These four possibilities are not mutually exclusive (Dick-
enson 1994a). Thus, in a particular pain state where opioids
are used to treat the pain, NMDA mediation of spinal
transmission may be occurring at the same time as elevated
spinal CCK and dynorphin levels with high plasma M3G
levels (Dickenson 1991). The evidence for and against
these systems altering opioid analgesia will be considered in
turn.
5.1. Morphine metabolites. The actions of morphine do not
end with metabolism. It is now well established that the
glucuronidation of morphine produces two major metabo-
lites, morphine-3-glucuronide and morphine-6-glucuronide,
each with remarkably different actions. The 6-glucuronide
is more potent than morphine itself, and although the
degree of this enhanced action is variable from study to
study, it is at least 10 to 30 times more effective in tests
of analgesia (Sullivan et al. 1989b). The reasons for this are
not obvious; the affinity of morphine-6-glucuronide for the
mu receptor is not appreciably greater than morphine itself,
although it has more delta and less kappa affinity. However,
as discussed earlier with morphine, it is likely that predomi-
nant mu activity underlies the analgesia with morphine-like
opioids at therapeutic doses. Yet the other metabolite, M3G
(morphine-3-glucuronide), has no affinity for the mu re-
ceptor and being unable to bind to the receptor has no
opioid actions. Results from behaviour after administration
of M3G have nevertheless led to the suggestion that M3G is
a factor that contributes to reduced opioid sensitivity (Gong
et al. 1992; Smith et al. 1990). The metabolite given by the
intraventricular route caused marked behavioural agitation
that interfered with the tests. In contrast to these studies,
there is electrophysiological (where nonspecific effects are
less likely to interfere with the results) and behavioural
evidence that even with dose ratios of 100:1 (metabolite to
morphine), M3G has absolutely no effect on the spinal
antinociceptive effects of morphine (Hewett et al. 1993). It
is highly unlikely that M3G is an important factor in cases of
opioid poorly responsive pain, since (1) the spinal site of
action of morphine is a major contributor to systemic
analgesia, (2) M3G does not bind to opiate receptors, and
(3) in renal insufficiency, where the metabolite will accu-
mulate, opiate effects tend to be enhanced. Thus M3G
should not, at present, be used as an excuse not to persevere
with or increase the dose of morphine in pain states where
opioid responsivity is poor. Patient-controlled analgesia has
revealed that neuropathic pain patients can gain relief with
morphine – although within this patient group pain control
is not as good as in patients with nociceptive pains ( Jadad et
al. 1992). Dose escalation can also be effective (Portenoy et
al. 1990).
5.2. Antiopioid peptides. Among the numerous factors
influencing morphine analgesia, accumulating evidence
indicates that the nonopioid peptide cholecystokinin
(CCK) is an important physiological modulator of analge-
sic mechanisms. The exogenous spinal application of CCK
and another peptide, FLFQPQRFamide, both nonopioid
peptides found within intrinsic neurones in the spinal cord,
will prevent mu- but not delta-mediated neuronal inhibi-
tions (Baber et al. 1989; Dickenson 1994a), and both
reduce intrathecal morphine analgesia in behavioural
studies (Xu et al. 1993). Thus in situations where there is a
release of these peptides one would expect a reduction in
morphine effects without requiring any change in opioid
receptor number. In fact, the ability of these peptides to
interfere with analgesia is not restricted to the effects of
opioids but also includes alpha-adrenoceptor agonist ac-
tions.
CCK has been shown to reduce the analgesic effects of
morphine at a number of CNS sites and has also been
implicated in the development of opioid tolerance (Baber
et al. 1989). Spinal and supraspinal delta opioid mediated
analgesias are not altered by CCK and, as a result, if there
are physiological situations where CCK reduces mu opioid
actions, future clinical delta agonists could be effective.
One of the key sites for these interactions is the spinal
cord. Negative results with cDNA probes within dorsal root
ganglia in the normal rat make it very unlikely that genuine
CCK is found in nociceptive C-fibres in normal animals.
Surprisingly, induction of the peptide in afferents occurs
after pathological damage to the afferents. The conse-
quences of this with regard to neuropathic pain (Xu et al.
1993) are discussed later in this section. Endogenous CCK
in the dorsal horn under nonpathological conditions is
thought to originate from both intrinsic neurones found in
superficial laminae and descending fibres. The receptors
are found both presynaptically (approximately 50%–60%)
and postsynaptically to the primary afferent fibres, mirror-
ing the mu opiate receptor distribution in the rat spinal
cord. The postsynaptic CCK receptors are mainly of the
CCKB type in the rat spinal cord but of the A-type in the
primate, whereas the presynaptic receptors are of the
CCKB type in all species. (Ghilardi et al. 1992). Thus CCKB
receptor antagonists will be critical in testing whether CCK
influences morphine analgesia in humans (Stanfa et al.
1994).
The mechanism by which CCK attenuates the anti-
nociceptive effect of morphine is not on opioid receptors
but via activation of CCK receptors that may then interfere
with opioid actions via postreceptor mechanisms. Key sites
for these CCK-opioid interactions are likely to be the spinal
terminals of C-fibres. Here, one possibility is that CCK
mobilizes calcium from intracellular stores. This will coun-
ter the opioid suppression of the rise in internal calcium
produced by depolarization, the basis for opioid reductions
in transmitter release. Again, CCK only reverses the sup-
pression of the induced rise in [Ca21]i produced by mu but
not delta opioid agonists (Wang et al. 1992).
At the same time, there is evidence for another mecha-
nism in the CCK–opioid interaction that involves the
endogenous enkephalins acting on the delta opioid recep-
tor. Here, both CCK antagonists and the presence of
inflammation (see below, this section) enhance morphine
analgesia, an effect that is prevented by delta opioid antago-
nists. The theory is, then, that CCK inhibits the release of
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enkephalins – removal of this control allows the increased
levels of the enkephalins to cause a delta-receptor-
mediated synergy with the mu receptor (Ossipov et al.
1995; Vanderah et al. 1994). Both theories are not mutually
exclusive.
In keeping with CCK reducing opioid analgesia, the
ability of morphine to inhibit spinal nociceptive processing
is enhanced in the presence of selective CCKB antagonists,
demonstrating physiological antagonism of morphine anti-
nociception by endogenous CCK under conditions of acute
nociception. There is now evidence for this interaction in
animal models more relevant to clinical situations such as
inflammatory and neuropathic pain models (Ossipov et al.
1995; Stanfa et al. 1994).
As discussed earlier, in neuropathies morphine tends to
have a reduced effectiveness, whereas after inflammation
morphine has enhanced actions. In fact, a few hours after
carrageenan inflammation there are mild increases in the
potency of delta and kappa opioid effects but marked
increases in the effects of morphine (Ossipov et al. 1995;
Stanfa et al. 1992). One reason is that due to the novel
peripheral action of opioids and systemic dosing, studies
will be confounded by this additional site of action. How-
ever, spinal morphine is almost 20 times more potent than
in normal rats after carrageenan inflammation. The mecha-
nisms for this latter effect must be central and rapidly
induced; the increased opioid actions occur within one hour
of the inflammation, ruling out receptor upregulation
(Stanfa et al. 1992). In this model, exogenous CCK still
attenuates the antinociceptive effects of morphine but
CCK receptor antagonism no longer produces an enhance-
ment of the antinociceptive effect of morphine. The most
likely basis for these results is a decreased availability of
CCK within the spinal cord following carrageenan inflam-
mation, either due to a decreased release of CCK or
reduced content within the dorsal horn. This reduced
functional activity of CCK in inflammation is therefore a
major factor in the enhanced potency of spinal morphine
seen in these animals (Stanfa & Dickenson 1993). In exactly
the same model there is also an increased alpha-2 inhibitory
tone in the spinal cord. Yet in this case, antagonist studies
have shown that noradrenergic activity is not a factor in the
altered opioid sensitivity, although it may well reduce
inflammation-induced nociception (Stanfa & Dickenson
1994a).
Neuropathic models reveal that CCK plays an entirely
opposite role. In nerve damage, increases in CCK systems
have been shown to underlie observed reductions in spinal
opioid sensitivity. It has been shown that an increase in
spinal CCK (likely to be due to novel synthesis of the
peptide in primary afferent fibres; see Xu et al. 1993) leads
to a reduction in the potency of spinal morphine in a rat
model of neuropathic pain following peripheral nerve in-
jury. If the increased CCK is derived from induction of the
peptide in the afferents, the interference would seem to be
directed at the presynaptic mu receptor. The opioid respon-
siveness of this model was restored by CCKB antagonism.
Different pain states may then lead to changes in the levels
and synthesis of CCK that can shift opioid sensitivity in
either direction (Stanfa et al. 1994). An important point that
arises from these studies is that the attenuation of opioid
analgesia by CCK is not global but selective for mu but not
for delta opioid receptor events. The prediction would be
that delta opioids may have efficacy in pain states where
morphine is poorly effective due to enhanced CCK
levels.
CCK may then be an endogenous “brake” applied to the
antinociceptive actions of morphine. In addition to the
alterations in CCK induced by different pain states, behav-
ioural studies have suggested that the release of endoge-
nous CCK is even governed by the environment to which an
animal is exposed. It is suggested that CCK released in
“safe” situations prevents the acute antinociceptive effects
of mu agonists and thus reduces the effects of morphine
(Wiertelak et al. 1992). Findings such as these may provide
a basis to understand how events such as stress and anxiety
alter opioid efficacy. Whatever the case, these studies serve
to indicate that the release of CCK is not fixed but varies, in
both directions, from its normal state according to both
external and internal events.
It appears, therefore, that CCK can act to control spinal
morphine analgesia. Attenuation of this negative influence
leads to augmented spinal opioid controls. This augmenta-
tion, along with the novel peripheral actions of opioids in
inflammation and enhanced descending controls, could be
an adaptation of intrinsic inhibitory systems to balance
enhanced nociception during inflammatory states. In con-
trast to the natural physiological processes of inflammation,
the pathological changes in neuropathic pain states result in
counterproductive increases in CCK. CCK antagonists cur-
rently developed by the pharmaceutical industry may well
enhance morphine analgesia in nonpathological pain states
and restore morphine analgesia in humans with neuro-
pathic pains. The predicted anxiolytic effects of these
antagonists would be a bonus when used as analgesic
adjuncts especially in states of chronic pain where anxiety
commonly accompanies pain (Stanfa et al. 1994).
5.3. Dynorphin. In inflammatory states there is an increase
in the mRNA in the spinal cord for dynorphin and, to a
lesser extent, for enkephalin with all the cells increasing
dynorphin synthesis having a preceding rise in c-fos, a
protooncogene (Dubner & Ruda 1992). Dynorphin can
mimic some of the increases in excitability seen after
inflammation, such as the increased nociceptive responses
of neurones, while inhibiting others (Knox & Dickenson
1987). Kappa opioids can functionally antagonize the mu
receptor in the spinal cord, potentially contributing to a
decreased morphine effectiveness even though opioids are
more potent in inflammatory models (Stanfa et al. 1992).
Furthermore, increases in spinal dynorphin levels also
occur in neuropathic states where opioid actions tend to be
reduced. These generally increased dynorphin levels in
different physiological pain models, where opioid actions
can be increased or decreased depending on the model,
make kappa antagonism of morphine unlikely to be of
physiological significance. What the functional conse-
quences of the increases in dynorphin mean to the spinal
cord is not known (Stanfa & Dickenson 1994b), and since
dynorphin can elicit NMDA-receptor-mediated effects as
well as opioid actions (see Dubner & Ruda 1992), the
picture is complex. Figure 1 depicts some of these opioid
interactions with spinal circuitry.
6. Central hypersensitivity
One of the most important new concepts related to pain is
the idea that the ascending and propriospinal pain mes-
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Figure 1. The diagram depicts the interactions between the
different pharmacological systems described in section 5. Activity
generated in peripheral sensory nerves releases a number of
transmitters into the dorsal horn of the spinal cord. Their receptor
actions and interactions, subject to control by local and supraspinal
pathways, determine the output from dorsal horn projection
neurones. Many of these systems are subject to plasticity.
sages from the dorsal horn are not the same under all
circumstances. We are nearing explanations for the extreme
aberrations of pain transmission – such as phantom limb
pains, hyperalgesias, and allodynias – where the relations
between the stimulus and the response are markedly per-
turbed. The basis for this lack of strict concordance be-
tween stimulus and response appears to be the generation
of central hypersensitivity (Dickenson 1994b; McMahon
et al. 1993; Price et al. 1994b; Woolf 1994; Woolf &
Thompson 1991).
There are two key observations on this subject. First,
high-frequency C-fibre stimuli result in a marked and
prolonged increase in the flexion withdrawal reflex in rats
recorded from motoneurones in spinal animals (Woolf
1983). Thus, noxious stimuli can enhance spinal excitatory
events. Second, the repetition of a constant intensity C-
fibre stimulus induces the phenomenon of “wind-up,”
whereby the responses of certain dorsal horn nociceptive
neurones suddenly increase markedly (both in terms of
magnitude and duration) despite the constant input into the
spinal cord (Dickenson 1994b). Volatile general anaesthesia
such as with halothane fails to prevent this type of activity,
indicating that the treatment of postoperative pain states
needs to take into account potential priming events occur-
ring during the operations. The object of this account is to
discuss the possible pharmacological substrates underlying
these changes.
6.1. Substrates for central hypersensitivity
6.1.1. Peptides. Historically Substance P (SP) was the first
transmitter to be related to the transmission of pain. SP
release can be detected in the spinal cord following high-
but not low-intensity peripheral stimulation. The use of
antibody microprobes to detect the spatial release of SP has
shown that it is essentially restricted to the zones where the
C-fibres terminate (Duggan et al. 1988). In addition to
substance P, the release of neurokinin A and CGRP follow-
ing C-fibre activation has been demonstrated. However,
when CGRP is present the subsequent release of SP is now
extended to cover much of the dorsal horn. The interpreta-
tion of this finding is that the degradation of SP is reduced
by CGRP binding to the peptidase that also cleaves SP,
allowing SP to diffuse in the active form over considerable
distances (Schaible et al. 1992). The concept of actions at a
distance from the release site, so-called volume transmis-
sion, has attracted interest as a basis for nonsynaptic trans-
mitter actions. Events such as these may have relevance to
pain as the peptides may diffuse to distant receptors,
avoiding both peptidases and spatially restricted inhibitory
influences. The induction of inflammation is accompanied
by enhanced release of these peptides centrally, which may
then contribute to the central hypersensitivity (Dray et al.
1994; Sluka et al. 1992; Todd & Spike 1993).
The postsynaptic receptors for the neurokinin family of
peptides, substance P, and neurokinins A and B are now
well characterized (Otsuka & Yoshioka 1993). Cloning and
sequencing have been achieved. Currently it is understood
that there are three subclasses of tachykinin receptors: the
neurokinin 1, – 2, and – 3 receptors. Early studies on the
role of SP in neuronal events in nociception were bedeviled
by poorly selective antagonists and nonspecific effects of
the drugs. More recent studies have indicated a role of SP at
the NK1 receptor in different types of more prolonged
nociceptive transmission, including slow excitatory post-
synaptic potentials induced by repetitive C-fibre stimula-
tion and C-fibre-induced reflex facilitation. Similarly, the
NK1 receptor antagonist RP67580 has only weak actions on
acute responses but produces marked inhibitions of the
formalin response of the dorsal horn neurones with equiva-
lent effects on the two phases of the response. These recent
studies would indicate that the ability of NK1 receptor
antagonists to reduce the activation of dorsal horn neurones
depends on the type of stimulation used (Otsuka &
Yoshioka 1993). A consensus is that the conditions for the
release of substance P from the fine afferents include a
sufficiently long stimulus at an intensity sufficient to acti-
vate C-fibres (Urban et al. 1994). The acute responses of
the neurones must therefore include some other transmit-
ter; the evidence implicates glutamate and aspartate. We
lack antagonists for the other peptides, but some, such as
galanin and neuropeptide Y, are induced in afferents after
nerve damage (Todd & Spike 1993; Urban et al. 1994).
6.1.2. Excitatory amino acids. A large proportion of pe-
ripheral sensory fibres including both small and large fibres
contain glutamate and aspartate (Battaglia & Rustioni
1988). In the case of the C-fibres, the coexistence of
glutamate with peptides (Battaglia & Rustioni 1988) makes
it highly likely that a noxious stimulus releases both pep-
tides and excitatory amino acids from the afferent nocicep-
tive fibres. Thus in clinical pain states postsynaptic activa-
tion of both neurokinin and other peptide receptors
together with the receptors for the excitatory amino acids
on nociceptive neurones will occur. The development of
selective agents for the receptors – the N-methyl-
d-aspartate (NMDA), the metabotropic, and the alpha-
amino-3-hydroxy-5-methyl-isoxazole (AMPA) receptors –
has enabled their roles in spinal processing to be studied.
The metabotropic receptor still has an ill-defined role in
pain states but may well contribute by acting to enhance
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NMDA and AMPA receptor function via intracellular ac-
tions. Use of AMPA receptor antagonists indicate that acute
noxious but also innocuous stimuli seem to be transmitted
via AMPA receptor activation (Dougherty et al. 1992;
Neugebauer et al. 1993). The widespread roles of AMPA
receptors in CNS function and the lack of nociceptive
selectivity mean that the receptor as a therapeutic target
looks doubtful. In contrast, the NMDA receptor has be-
come an increasingly important target site as evidence
accumulates for a role of the receptor in the enhancement
of spinal processing of painful messages (see Dickenson
1990; 1994b; Price et al. 1994a; 1994b) as well as a target
site in many long-term events in the brain (Collingridge &
Singer 1990; Daw et al. 1993). In the spinal cord, the
NMDA receptor may play a similar role, especially in more
prolonged pain states involving hypersensitivity where
functional alterations in central transmission processes may
occur.
The complexity of the NMDA receptor-channel is strik-
ing. In order to operate it, certain specific conditions need
to be met: The release and binding of the coagonists for the
receptor, glycine and glutamate, are needed together with a
non-NMDA-induced depolarisation to remove the resting
magnesium block of the channel (Dickenson 1994b).
C-fibre-induced release of excitatory peptides, either in a
restricted spatial zone or via volume transmission, may
provide the required depolarisation to remove the block,
since neurokinin receptor antagonists can reduce NMDA-
mediated responses in the spinal cord (Urban et al. 1994).
For these reasons, the NMDA receptor-channel complex is
not a participant in “normal” synaptic transmission. Yet
when the correct conditions are achieved, the complex will
suddenly become activated and add a powerful depolaris-
ing or excitatory drive to transmission of pain in the spinal
cord, which then appears to lead to enhanced synaptic
transmission or hypersensitivity (Dickenson 1990; 1994a;
1994b; Dubner & Ruda 1992; McMahon et al. 1993;
Neugebauer et al. 1993; Price et al 1994a; 1994b; Woolf &
Thompson 1991). Increased release of afferent peptides in
inflammation, for example, could facilitate NMDA trans-
mission by more effective removal of the magnesium block
of the receptor channel or by increasing the release of the
excitatory amino acids themselves (Kangra & Randic 1990).
It is now well established that wind-up and the reflex
hypersensitivity are NMDA receptor mediated. Further
experiments with formalin indicate that when inflammation
is present, “pathological pain” can be distinguished from
the acute phase response where there is no damage on the
basis of the sensitivity of only the former to NMDA antago-
nism. Both the induction and the subsequent maintenance
of these responses are dependent on NMDA processes
(Haley et al. 1990; Neugebauer et al. 1993; Price et al.
1994b).
However, NMDA receptor activation can also influence
inhibitory interneurones in the spinal cord; evidence for
this appears from carrageenan inflammation where exces-
sive NMDA receptor activation subsequently induces in-
hibitory influences (Stanfa et al. 1992). Excessive NMDA
activation in the CNS is one mechanism behind excitotox-
icity and, as a result, elevated NMDA activation may trigger
inhibitory systems as an auto-limiting device to prevent
over excitation and even cell death. Possibly, the loss of
inhibitions to counter NMDA excitatory mechanisms
(Woolf & Doubell 1994) leads to some of the problems of
neuropathic pain. In this regard, NMDA-mediated al-
lodynia can be induced by a blockade of spinal inhibitory
tone in normal animals (Yaksh 1989). Furthermore, failure
of inhibitions could underlie the transition from acute to
chronic pain.
Other approaches have revealed roles of the NMDA
receptor in spinal pain processes including ischaemia and
neuropathic pain states, where NMDA antagonists have
beneficial effects weeks after induction of the injury against
the hyperalgesia and spontaneous pain. Thus, there is
evidence for an involvement of the NMDA receptor in
inflammatory pain, neuropathic pain, allodynia, and is-
chaemic pain. Not only can wind-up be demonstrated in
elegant psychophysical studies in humans (Price et al.
1994a) but, crucially, recent evidence also has shown an
NMDA dependency of allodynias and wind-up pains in
controlled clinical studies (Eide et al. 1994).
6.1.3. Nitric oxide and arachidonic acid. Central plasticity
can also involve a gas. Nitric oxide (NO), a diffusible gas, is
produced in response to NMDA receptor activation and
thus may mediate some or all of the consequences of
NMDA receptor activation in nociception (Meller & Geb-
hart 1993). Blockers of nitric oxide synthase (NOS) are
effective against inflammatory and neuropathic nocicep-
tion in animals by spinal actions. There are hints that NO
may feed back and enhance the release of the afferent
transmitters and as a result set up a positive feedback loop
(Sorkin 1993). In addition, an induction of NO in the
afferents has been reported after nerve damage. Spinal
production of arachidonic acid in response to C-fibre stim-
ulation and NMDA receptor activation may achieve the
same end; prevention of this could underlie some of the
central analgesic effects of nonsteroidal anti-inflammatory
drugs (NSAIDs) (Malmberg & Yaksh 1992).
The evidence for spinal actions of NSAIDs continues to
grow. This growth is based not only on the demonstrations
of C-fibre-evoked and, more importantly, NMDA-evoked
release of prostanoids, but also on the spinal action of
NSAIDs that can be shown by intrathecal administration of
these agents. In addition, it has been shown that the
hyperalgesia produced by NMDA and substance P is re-
duced by spinal NSAIDs (Malmberg & Yaksh 1992). As
there is evidence for prostanoid-, NO-, and NMDA-
mediated release of glutamate and substance P, it would
appear that the production of novel mediators by NMDA
receptor activation underlies retrograde messenger control
of transmitter release (Sorkin 1993).
There will be problems with NOS blockers in therapy,
since NO is an endothelium-derived relaxing factor and
systemic administration may induce analgesia but will be
accompanied by severe hypertension. However, it has been
demonstrated that neuronal NOS differs from that in the
endothelium and thus it may be possible to separate these
effects.
7. Consequences of central hypersensitivity
The presently characterized systems operate in the spinal
cord, which appears to mediate central hypersensitivity, a
state where amplification and prolongation of the afferent
barrage occurs. The established roles of these different
transmitter systems may offer novel targets for therapy.
This may be important since wind-up, the hypersensitized
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reflex, and several measures of NMDA-dependent activity
in neuropathy and allodynia models can be poorly sensitive
to opioids (Dickenson 1994b). As discussed earlier, the
reasons may be nociception through channels not con-
trolled by opioids (large fibre-induced allodynias), high
levels of excitability (NMDA-mediated amplification), or
pathological loss of the opioid receptors.
7.1. Treating opioid poorly responsive pain. The first
approach is based on animal studies showing that loss or
dysfunction of presynaptic opioid receptors can be over-
come by increasing the dose of opioid (Lombard & Besson
1989; Xu & Wiesenfeld-Hallin 1991). In addition, in pains
where the NMDA receptor is operating and there is re-
duced opioid sensitivity (as in some of the models for
inflammatory and neuropathic pain), this too can be over-
come by dose escalation (Chapman & Dickenson 1992;
Yamamoto & Yaksh 1992). The simple augmentation of the
dose of morphine should be first tried, although side effects
may confound this tactic. Another approach may be the use
of high-efficacy opioids such as alfentanyl or sufentanil, but
data is lacking on this point. If opioids cannot produce the
desired effects, different pharmacological approaches are
possible: In the case of the NMDA receptor there are many
experimental drugs that effectively block the receptor, the
channel, or associated sites. Some of these are in develop-
ment as potential drugs, but there clearly is a need for
agents to be tested now. In fact, ketamine blocks the
channel associated with the NMDA receptor and has cur-
rent use in the relief of pain. Dextrophan and dex-
tromethorphan are also antagonists at this site and are
currently used in humans for their antitussive effects.
Both have been shown to reduce wind-up itself (Dickenson
et al. 1992) as well as to be effective in the Bennett model
of neuropathic pain after spinal application (Mao et al.
1993; Tal & Bennett 1993) and in humans (Price et al.
1994a). Recently, the anti-Parkinson drug, memantine, has
been shown to be an effective NMDA antagonist. All could
be used to test the clinical effectiveness of NMDA blockade
in opioid poorly responsive pains. However, the NMDA
antagonists would be effective only in reducing hyper-
algesia, not in abolishing the pain (Dickenson 1994b).
These agents may turn out to be especially useful in the
allodynias, which are sensitive to NMDA receptor antago-
nists but not to opioids. In fact, not only is there psy-
chophysical evidence for wind-up pain in humans being
mediated by NMDA receptors, based on studies with
dextromethorphan (Price et al. 1994a), but there is also
evidence from clinical trials showing that ketamine can
reduce allodynias, hyperalgesias, and cause pain relief in
circumstances where opioids had poor or restricted efficacy
(Eide et al. 1994).
One practical application of the poor opioid responsive-
ness of NMDA-mediated pains is that the coadministration
of morphine with low doses of an NMDA antagonist should
be beneficial in these pain states. This is indeed the case;
furthermore the combination has been shown to synergize
in one study (Chapman & Dickenson 1992) and be additive
in another model (Yamamoto & Yaksh 1992). However,
both studies have shown that the additional NMDA antago-
nism restores the opioid sensitivity of the responses. In
addition, spinal local anaesthetics synergize with spinal
morphine (Akerman et al. 1988), partly due to the ability of
the former to reduce NMDA-mediated activity (Fraser et
al. 1992). The spinal release of prostaglandins affords
another target, and centrally acting NSAIDs have been
shown to reduce persistent inflammatory nociception and
the behavioural hyperalgesia produced by spinal substance
P and NMDA. Predictably, NSAIDs will synergize with
opioids (Yaksh & Malmberg 1994).
It has been suggested that once these central hypersen-
sitivity states have been induced, they remain active in the
absence of peripheral inputs (Coderre et al. 1990). There is
counterevidence from both animal studies and in human
pain states where there is clear evidence for central changes
that are entirely dependent on peripheral inputs for main-
tenance (Dickenson & Sullivan 1987; Gracely et al. 1993).
Thus it would seem that the central pain hypersensitivity
generators are continually triggered by afferent activity.
Consequently, there is a place for peripheral local anaesthe-
tics although the symptoms may well reappear once the
block wears off. In addition, there is evidence that systemic
local anaesthetics may have selective effects on ectopic foci
in a damaged peripheral nerve at doses that do not alter
conduction in the nerve (Devor et al. 1992). Finally, as
stated earlier, spinal sites of action of local anaesthetics
include a reduction in wind-up (Fraser et al. 1992).
In all of these studies on opioid poorly responsive pain,
the emphasis has been on mu opioids, especially morphine;
yet mu and delta opioids and alpha-2 agonists all have
similar effects on wind-up, reducing the initial responses of
the cells but with wind-up breaking through the inhibitions
as the stimulation continues and restoring the cell re-
sponses (Dickenson 1991; 1994a). It is unlikely, therefore,
that these three systems would have differential effects on
NMDA-receptor-mediated events, making drugs such as
clonidine unlikely to be alternatives to morphine, at least
with regard to spinal events where the NMDA receptor is
implicated. In addition, the negative effects of CCK on
analgesia are not only directed against mu opioids but also
alpha-2 adrenoceptors. However, it is possible that in cases
where presynaptic opioid receptors are reduced, such as in
cases of peripheral nerve pathology, alpha-2 receptors may
persist at postsynaptic sites and thus provide a therapeutic
target. Relatedly, there may well be sympathetic blocking
effects of clonidine via systemic routes as well as the spinal
route, which will be of importance in sympathetically main-
tained pains. Yet again, alpha-2 adrenoceptor agonists pro-
duce powerful potentiations of opioid analgesia (Dickenson
& Sullivan 1993; Yaksh & Malmberg 1994).
7.2. Preemptive analgesia. The idea of preemptive analge-
sia has arisen due to the potential for induction of hypersen-
sitivity, genes, and negative influences on opioid controls in
addition to the well-established detrimental effects of the
stress and hormonal responses to pain. Thus, treating pain
before it arises rather than waiting for it to develop appears
to have a rational basis (Woolf 1994). Animal studies lend
support to this: several measures of central hypersensitivity
are less sensitive to opioids given as a post-treatment as
compared to preemptive administration (Chapman et al.
1994). Restricting comments to the use of opioids, there are
several reasons why the clinical studies on preemptive
analgesia have been either negative or have showed rela-
tively weak benefits (Dahl 1994; McQuay 1994). Most have
used postoperative pain measures and invariably operative
procedures will induce inflammation.
The key issues in comparing pain relief pre- and post-
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operatively are the exact timing of administration and that
baseline opioid sensitivity remains the same (McQuay
1994). With the former, it may be that a pretreatment is the
same as an early posttreatment, as they both will preempt
late-developing central hypersensitivity. Studies with var-
ied timing of opioids on the formalin response support this
idea (Chapman et al. 1994). With opioid sensitivity, it is well
established in animal models of carrageenan inflammation
and arthritis that not only is novel peripheral opioid recep-
tor mediated analgesia rapidly revealed but also spinal
opioid sensitivity is enhanced, just as rapidly (Stanfa et al.
1992; Stein 1994). Thus post-treatment with opioids will
impinge upon enhanced opioid systems and comparisons
with the effectiveness of pretreatments will be biased. In
neuropathic pains, where in general opioid sensitivity is
reduced, inhibitions are lost, and central and sympathetic
processing is aberrant, the impact of pretreatment is far
more obvious.
7.3. The roles of inhibitions. When NMDA-mediated cen-
tral events leading to hypersensitivity are active in the
shorter-term models (formalin and the hypersensitive re-
flex), there is a reduced sensitivity to opioids; whereas once
several hours have elapsed (carrageenan and arthritic in-
flammation), opioid sensitivity is now found to be in-
creased. In the example of the former models, dose-
escalation can overcome the reduced opioid sensitivity
(Chapman et al. 1994). The reasons for these differences
could reside in the unchecked NMDA receptor mediation
of activity in the shorter-term models, for example, for-
malin, prior to the induction of the slower-developing
inhibitory changes, overcomes opioid inhibitions. The com-
pensatory increases in spinal opioid sensitivity (via altered
CCK) and other inhibitions means that the longer term
acute pains respond well to opioids. This is partly due to the
enhanced opioid effectiveness per se but also because the
increased nonopioid (GABA and alpha-2 adrenoceptor
mediated) inhibitory events will reduce the NMDA-driven
level of excitability (Castro-Lopes et al. 1994; Stanfa et al.
1994). A good example of the potential controlling influ-
ence of inhibitions is seen in the formalin response. NMDA
receptor activation in the spinal cord amplifies a low level of
C-fibre input (Heapy et al. 1987) to generate the charac-
teristic response. The resultant behavioural and neuro-
physiological responses to the peripheral injection of for-
malin last for one hour, but the C-fibre inputs continue for
over two hours and the peripheral inflammation for even
longer periods (Porro & Cavazzuti 1993). The central
responses must surely be curtailed by inhibitory controls. If
the plastic changes are leading to compensatory increased
central inhibitions such as these, then preemptive ap-
proaches may prevent both this beneficial plasticity as well
as the target of central hypersensitivity mechanisms. If this
is the case, as the preemptive agent wears off, the pain may
return in the absence of compensatory inhibitions and thus
with greater intensity.
Whereas the roles of inhibitions have generally received
less attention than the excitatory systems, in an animal
model of allodynia, NMDA antagonists unlike morphine
are effective against tactile-evoked nociception (Yaksh
1989). In this model the NMDA-mediated allodynia is
induced by a blockade of spinal GABA or glycine inhibitory
tone in normal animals. This has bearing on the previously
made point that inhibitions are important in controlling and
limiting the extent of NMDA receptor participation in
nociceptive processing in the spinal cord. Increasing GABA
function by the administration of benzodiazepines reduces
NMDA-mediated hyperalgesia after ischaemia (Cartmell
& Mitchell 1993); another intriguing example of this is the
enhanced NMDA-mediated nociception seen when spinal
glycine inhibitions are blocked in a neuropathic model in
the rat (Seltzer et al. 1991). In contrast, GABA upregulation
may be an intrinsic compensatory mechanism in longer-
term inflammation (Castro-Lopes et al. 1994).
Failure of these and other inhibitory controls conceivably
may lead to chronicity of pain. In fact there is strong
evidence that the hyperalgesia seen in neuropathic models
is as much a consequence of loss of inhibitions and reorga-
nization as excess excitations (Dray et al. 1994; Woolf &
Doubell 1994), which could be due to a destructive loss of
inhibitory interneurones – itself exacerbated by phar-
macological block of these inhibitory systems (Sugimoto et
al 1990).
8. Developmental aspects
Examination of events in the neonatal spinal cord are of
great relevance to the role of modulatory systems in con-
trolling excitation, since the maturation of the inhibitory
systems is slow. Paediatric pain control has to take into
account the findings that the development of the nervous
system is accompanied by marked changes in many trans-
mitters and receptors over time. A number of studies on the
anatomical and functional development of the excitatory
and inhibitory pharmacology of the rat and human spinal
cords suggest that the rodent provides a good model for
investigating clinical questions (Fitzgerald 1991).
Studies using the neonatal spinal cord have shown that all
the excitatory and inhibitory receptors covered in this
account are functional at day one in the rat; many of these
neuropharmacological systems are present even before
birth. Full maturation of the endogenous transmitter path-
ways and connections is much slower (Marti et al. 1987),
particularly the local inhibitory and long descending con-
trols. The levels of excitatory transmitters, such as sub-
stance P and excitatory amino acids including glutamate,
tend to increase during development. At the same time NK
and NMDA receptor location in young animals is far more
exuberant than in adults, and their numbers decline with
time as the receptors shrink back to assume the discrete
adult form (Charlton & Helke 1986). Dendritic develop-
ment, interneurones (Bicknell & Beal 1984), and descend-
ing inhibitory controls (Fitzgerald & Koltzenburg 1986) are
slowly developing so that modulation of excitability is de-
layed. The conclusion from these studies is that the trans-
mission of pain in the spinal cord of the young is likely to be
exaggerated compared to the adult as a result of excess early
development of excitation and delayed maturity of the
intrinsic controlling inhibitory systems.
This difference between the young animal and the adult
can be seen once more by using the formalin response, but
now in neonatal rats (Guy & Abbot 1992). In the first week
of life, the response to peripheral algogen is dramatic and
disruptive to normal behaviour. As development proceeds,
response declines – until at about three weeks, when
inhibitory systems have matured and response resembles
the more discrete adult form.
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Opioids and their three receptors also change with time:
the relative arrival of the mu, delta, and kappa receptors
differs as does the development of the endogenous opioids.
Although the opioid receptor affinities resemble the adult
at very early stages, the numbers of receptors decline over
time (Attali et al. 1990; Sales et al. 1989). The early
ontogeny of the opioid receptors means that there is a
substrate present for the production of analgesia by ex-
ogenous opioids, whereas the controlling influences of
endogenous opioid neuronal systems may only appear later
in development.
Thus the systems in the adult that generate spinal hyper-
sensitivity may be more effective in the young nervous
system, due to less inhibitory influences as a result of
immaturity of these systems. Exogenous activation of
opioid receptors allows pain in the young to be controlled
by adequate analgesia either with opioids alone or with
some of the combinations discussed previously. Because
activity-dependent plasticity is important in determining
maturation of connectivity in the developing nervous sys-
tem, it has to be considered that uncontrolled pain in the
young may have long-term consequences for the neurobiol-
ogy of pain. In this respect, fears regarding the conse-
quences of opioid use in young children, which are proba-
bly unfounded as suggested by the lack of dramatic effect
from early opioid exposure on later function (Bardo et al.
1982), pale into insignificance when compared to the pos-
sible permanent alterations in sensory processing that un-
controlled pain in the young could produce.
9. Conclusions
Many questions remain to be answered about events in
different pain states that can alter, in either direction, the
analgesic effects of opioids. As has been discussed, this
recently accumulating knowledge of plasticity provides a
rational basis for combination therapy (Dickenson 1994b;
Dickenson & Sullivan 1993; Yaksh & Malmberg 1994).
Examples given here fall into two categories: first, the
combination of opioids with other inhibitory agents such as
alpha-2 adrenoceptor agonists and, second, dual therapy
where the nonopioid acts to reduce excitability or to control
interfering systems (CCK and NMDA receptor antago-
nists, NSAIDs, local anaesthetics). Dual therapy such as
this has been shown to result in restoration, additivity, or
potentiation of opioid analgesia (Dickenson & Sullivan
1993; Yaksh & Malmberg 1994). It is also becoming increas-
ingly clear that particular pain states have different plas-
ticities; despite some similarities (e.g., NMDA mediation of
hypersensitivity), inflammatory and neuropathic pains are
not only very different from each other but cannot be
viewed as uniform syndromes. For example, in neuropathic
pains the human and animal studies on opioid sensitivity do
not reach a consensus; animal studies suggest both good
(Attal et al. 1991; Yamamoto & Yaksh 1992) and poor opioid
sensitivity – and the clinical studies are not totally in
agreement on this point either (Arner & Meyerson 1988;
Jadad et al. 1992; Portenoy et al. 1990). Particular mono-
therapies and combination therapies will likely be appropri-
ate for different states within a pain syndrome (McQuay &
Dickenson 1990). Other key points that need investigation
are the following: Does a repeated noxious insult alter the
plasticity? Knowledge is building up for the neonate, but
what happens in the ageing nervous system? The answers to
these and other questions relating to plasticity have impor-
tant consequences for the clinical treatment of pain.
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